Kiniksa Pharmaceuticals International, plc (KNSA)
NasdaqGS · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$72.98 (-4.89%) as of
Key statistics
- Market cap
- 5.69B
- P/E (TTM)
- 73.72
- Forward P/E
- 44.77
- EPS (TTM)
- 0.99
- Dividend yield
- 0.00%
- 52-week range
- 35.20 – 84.06
- Beta
- 0.04
- Revenue (TTM)
- 840.85M
- Profit margin
- 9.59%
- Analyst target
- $98.00
- Volume
- 1.43M
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- London, United Kingdom
- Employees
- 366
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.